LSB Industries, Inc. (LXU)
NYSE: LXU · Real-Time Price · USD
7.53
-0.20 (-2.59%)
Aug 14, 2025, 11:31 AM - Market open
CTI BioPharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $10.08, which forecasts a 33.86% increase in the stock price over the next year. The lowest target is $9.25 and the highest is $11.
Price Target: $10.08 (+33.86%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy → Hold Downgrades $9.25 | Strong Buy → Hold | Downgrades | $9.25 | +22.84% | Jul 23, 2025 |
| UBS | UBS | Strong Buy Maintains $11 → $8 | Strong Buy | Maintains | $11 → $8 | +6.24% | Apr 16, 2025 |
| Piper Sandler | Piper Sandler | Sell → Buy Upgrades $9 → $11 | Sell → Buy | Upgrades | $9 → $11 | +46.08% | Jan 13, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +32.80% | Nov 4, 2024 |
| UBS | UBS | Hold → Strong Buy Upgrades $9.5 → $11 | Hold → Strong Buy | Upgrades | $9.5 → $11 | +46.08% | Oct 10, 2024 |
Financial Forecast
Revenue This Year
580.11M
from 522.40M
Increased by 11.05%
Revenue Next Year
591.55M
from 580.11M
Increased by 1.97%
EPS This Year
0.33
from -0.27
EPS Next Year
0.11
from 0.33
Decreased by -68.18%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 658.9M | 647.9M | 662.6M | ||
| Avg | 580.1M | 591.6M | 635.1M | ||
| Low | 493.9M | 506.7M | 614.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.1% | 11.7% | 12.0% | ||
| Avg | 11.0% | 2.0% | 7.4% | ||
| Low | -5.5% | -12.7% | 3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.37 | 0.17 | 0.60 | ||
| Avg | 0.33 | 0.11 | 0.43 | ||
| Low | 0.30 | 0.05 | 0.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | -49.6% | 464.4% | ||
| Avg | - | -68.2% | 304.8% | ||
| Low | - | -85.3% | 158.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.